Ar­cutis' for­mu­la­tion of old As­traZeneca drug clears an­oth­er PhI­II test

Weeks af­ter rolling out its first pso­ri­a­sis treat­ment, Ar­cutis Bio­ther­a­peu­tics is rack­ing up more pos­i­tive Phase III da­ta for a sec­ond for­mu­la­tion of an old …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER